Roche licenses Simcere’s B-cell-targeting tri-specific for $1.53bn
The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential.
The antibody is designed to provide broad coverage across B-cell mediated diseases and might have autoimmune therapeutic potential.